Ongoing monitoring typically involves monthly or quarterly check-ins during dose titration, regular assessment of weight loss progress and tolerability, periodic lab work to monitor metabolic parameters, and screening for potential complications
10.1038/280843a0 46 SaltielA
The preference for injectable formulations is further supported by their ability to provide consistent drug levels, reducing the frequency of administration and enhancing patient compliance
In the United States, FDA guidelines indicate these medications for: Adults with a BMI of 30 or higher (obesity) Adults with a BMI of 27 or higher who also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea You should discuss GLP-1 medications with a physician if you have any of the following, as they may affect which medication is appropriate or require additional monitoring: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) a contraindication for all GLP-1 drugs History of pancreatitis Kidney disease or a history of gallstones Pregnancy or plans to become pregnant History of eating disorders The Critical Factor Most People Overlook: Muscle Loss Here is something that rarely appears in GLP-1 marketing: these medications can cause significant muscle loss alongside fat loss, particularly at the aggressive weight loss rates they enable
EGCG has the potential to treat a wide range of diseases, including diabetes, hypertension, and neurological illness, due to its anti-inflammatory and antioxidant capabilities (Wu et al
Peroxidation of specific membrane lipids is the ultimate driver of ferroptosis (Stockwell, 2022)
